Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Repare Therapeutics shares jumped in premarket trading after the company agreed to sell its polymerase theta ATPase inhibitor to Gilead Sciences for up to $30 million. Shares were 18% higher at $2.57 ...

Repare Therapeutics ( ($RPTX) ) has issued an update. On December 23, 2025, Repare Therapeutics entered into an asset purchase agreement under ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

Repare Therapeutics (RPTX) added ~20% in the premarket on Wednesday after the company announced an asset purchase agreement to sell its experimental cancer therapy RP-3467 to Gilead (GILD) in a deal ...

Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward. Back in January, Repare abandoned phase 3 plans to ...

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, ...

MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will ...

After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech ...

In addition to that upfront payment, the deal makes Quebec, Canada-based Repare eligible for up to $1.2 billion in milestone payments—$55 million of those payments are “near-term” milestones tied to ...